Seven business cases in nanotechnology were recently awarded a maximum of € 100,000 each to support the development of their venture. They were selected out of 12 candidates that made it to the final phase of the second call of the NanoNextNL Valorisation Programme. The awarded sum will be matched with an equivalent amount by NanoNextNL partners, comprising companies and knowledge institutes, bringing the total financing up to € 1.4 million.
Awarded business cases
In the course of 6 months, € 40,000 was invested in building and validating the business cases. Experts in the field of intellectual property, market research and business development contributed to the Valorisation Programme.
The following business cases were awarded in the second call of the NanoNextNL Valorisation Programme:
LipoCoat introduces the next generation in bio-inspired biomaterial coatings. In virtually all applications where living cells and tissue are brought into contact with man-made materials unwanted (side) effects are observed. This holds for in vivo medical devices such as implants and pacemakers, ex vivo devices such as catheters and contact lenses. In some cases this can result in bacterial attachment, growth and biofilm formation. Read more.
Within the logistics industries, autonomous mobile robots are replacing human labour. Affordable high accuracy localisation and navigation are the main drivers in creating the next generation robots. Determining the exact position of the robot in relation to the environment (e.g. goods in a warehouse) for a fully automated operation is both crucial and challenging. Read more.
Delft IMP (Intensified Materials Production) commercialises nanostructuring of particles based on the patented and publicised IP and know-how developed within the Product & Process Engineering (PPE) group at Delft University of Technology. Potential market segments where Delft IMP nanostructuring technology shows significant benefits include energy storage (increased lifetime for batteries), controlled release (targeted medication) and catalysis. Read more.
Surfix’s unique and proprietary surface modification technology is based on ‘triggered assembly’, which enables local and material-selective deposition of nanocoatings in a fast and simple process. This compares favourably to state of the art surface modification methods based on ‘self-assembly’, which yield homogeneous and uniform nanocoatings. Read more.
Driven by costs, quality and efficiency the clinical diagnostics is under pressure. Routine analysis are outsourced to centralised laboratories leaving behind laboratory with insufficient resources to analyse emergency samples that require highly trained and skilled lab technicians. The analysis of Cerebrospinal Fluid (CSF) and the detection of Sepsis in blood are two examples that are under large pressure. Read more.
The current sales of biotherapeutics is close to US$ 125 billion. Mammalian cells have been used for a long time in the production of biopharmaceuticals. In the current production processes of novel biopharmaceuticals cell handling is executed at the colony level (single-colony-based-breeding). However, these colonies are highly heterogeneous in nature due to the gene amplification process and random gene integration. Read more.
We present a compact and industry-compatible spectrometer for comprehensive diagnosis of Extreme Ultraviolet (EUV) and other short-wavelength light sources. Such diagnosis allows critical optimisation for producing higher EUV powers and lower undesired radiation towards achieving a higher chip production. Read more.